Palo Alto Investors’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-65,240
| Closed | -$1.95M | – | 34 |
|
|
2022
Q1 | $1.95M | Hold |
65,240
| – | – | 0.15% | 26 |
|
|
2021
Q4 | $1.73M | Hold |
65,240
| – | – | 0.11% | 29 |
|
|
2021
Q3 | $2.37M | Hold |
65,240
| – | – | 0.14% | 32 |
|
|
2021
Q2 | $2.83M | Hold |
65,240
| – | – | 0.16% | 30 |
|
|
2021
Q1 | $2.23M | Sell |
65,240
-34,576
| -35% | -$1.37M | 0.13% | 32 |
|
|
2020
Q4 | $3.49M | Sell |
99,816
-18,593
| -16% | -$538K | 0.18% | 28 |
|
|
2020
Q3 | $2.84M | Sell |
118,409
-235,846
| -67% | -$5.79M | 0.16% | 30 |
|
|
2020
Q2 | $6.48M | Hold |
354,255
| – | – | 0.39% | 23 |
|
|
2020
Q1 | $5.53M | Hold |
354,255
| – | – | 0.46% | 24 |
|
|
2019
Q4 | $7.58M | Sell |
354,255
-4,480
| -1% | -$92.2K | 0.42% | 22 |
|
|
2019
Q3 | $6.71M | Sell |
358,735
-39,860
| -10% | -$823K | 0.45% | 23 |
|
|
2019
Q2 | $10.4M | Hold |
398,595
| – | – | 0.51% | 25 |
|
|
2019
Q1 | $10.2M | Hold |
398,595
| – | – | 0.43% | 27 |
|
|
2018
Q4 | $9.17M | Buy |
398,595
+1,986
| +0.5% | +$56K | 0.49% | 26 |
|
|
2018
Q3 | $12.7M | Hold |
396,609
| – | – | 0.51% | 26 |
|
|
2018
Q2 | $11.2M | Hold |
396,609
| – | – | 0.45% | 26 |
|
|
2018
Q1 | $14M | Buy |
396,609
+3,051
| +0.8% | +$122K | 0.6% | 24 |
|
|
2017
Q4 | $15.3M | Buy |
393,558
+8,056
| +2% | +$307K | 0.66% | 25 |
|
|
2017
Q3 | $9.79M | Hold |
385,502
| – | – | 0.41% | 26 |
|
|
2017
Q2 | $10.5M | Sell |
385,502
-39,960
| -9% | -$1.09M | 0.49% | 25 |
|
|
2017
Q1 | $14.1M | Buy |
425,462
+7,800
| +2% | +$199K | 0.67% | 24 |
|
|
2016
Q4 | $9.94M | Sell |
417,662
-100,947
| -19% | -$2.89M | 0.57% | 23 |
|
|
2016
Q3 | $19M | Sell |
518,609
-20,044
| -4% | -$575K | 1.11% | 25 |
|
|
2016
Q2 | $12M | Buy |
538,653
+15,561
| +3% | +$387K | 0.91% | 27 |
|
|
2016
Q1 | $10.9M | Sell |
523,092
-820
| -0.2% | -$20.2K | 0.84% | 26 |
|
|
2015
Q4 | $15.9M | Buy |
523,912
+6,280
| +1% | +$190K | 0.88% | 24 |
|
|
2015
Q3 | $12.8M | Hold |
517,632
| – | – | 0.61% | 27 |
|
|
2015
Q2 | $16.6M | Hold |
517,632
| – | – | 0.74% | 27 |
|
|
2015
Q1 | $18.5M | Hold |
517,632
| – | – | 0.91% | 26 |
|
|
2014
Q4 | $11.8M | Sell |
517,632
-378
| -0.1% | -$7.64K | 0.69% | 30 |
|
|
2014
Q3 | $10M | Hold |
518,010
| – | – | 0.75% | 30 |
|
|
2014
Q2 | $18.8M | Buy |
518,010
+1,080
| +0.2% | +$36.7K | 1.4% | 20 |
|
|
2014
Q1 | $20.1M | Sell |
516,930
-4,770
| -0.9% | -$170K | 1.66% | 18 |
|
|
2013
Q4 | $14.9M | Sell |
521,700
-108,266
| -17% | -$3.18M | 1.39% | 18 |
|
|
2013
Q3 | $22.6M | Buy |
629,966
+236,408
| +60% | +$8.63M | 2.36% | 14 |
|
|
2013
Q2 | $13.1M | Buy |
+393,558
| New | +$17.8M | 1.55% | 17 |
|
Other funds holding RIGL
N
Palo Alto Investors's RIGL Position: Q2 2022 in Review
Palo Alto Investors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 65,240 shares — an estimated $1.95M sold.
Palo Alto Investors first reported a position in RIGL in Q2 2013 and held it in 36 quarters. The position peaked at $22.6M in Q3 2013. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.
- Palo Alto Investors reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
- Palo Alto Investors sold 65,240 Rigel Pharmaceuticals shares in Q2 2022, an estimated $1.95M.
- Palo Alto Investors first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 36 quarters.
- Palo Alto Investors's Rigel Pharmaceuticals position peaked at $22.6M in Q3 2013.
- 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.
Based on Palo Alto Investors's 13F filing for Q2 2022, filed 15 Aug 2022.